Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
about
Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infectionsArtemisinin combination therapy for vivax malariaThe use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malariaVivax malaria: neglected and not benignNovel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system.Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.Plasmodium falciparum gametocyte carriage is associated with subsequent Plasmodium vivax relapse after treatment.Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis.Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar borderPlasmodium vivax isolates from Cambodia and Thailand show high genetic complexity and distinct patterns of P. vivax multidrug resistance gene 1 (pvmdr1) polymorphisms.Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivaxPlasmodium vivax dhfr mutations among isolates from malarious areas of IranIn vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central ChinaIndividual Plasmodium vivax msp1 variants within polyclonal P. vivax infections display different propensities for relapse.Molecular Monitoring of Plasmodium vivax Infection after Radical Treatment in Southeastern IranThe plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs.Genetic analysis of the dihydrofolate reductase-thymidylate synthase gene from geographically diverse isolates of Plasmodium malariae.The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum.Malaria chemoprophylaxis: strategies for risk groupsProspects for the treatment of drug-resistant malaria parasites.Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapseThe role of anti-malarial drugs in eliminating malariaMicrogeographical differences of Plasmodium vivax relapse and re-infection in the Peruvian Amazon.Plasmodium vivax chloroquine resistance and anemia in the western Brazilian AmazonTherapeutic effects of antibiotic drug mefloquine against cervical cancer through impairing mitochondrial function and inhibiting mTOR pathway.Recent advances in the management of Plasmodium knowlesi infection.The threat of antimalarial drug resistance.Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey.Island-wide diversity in single nucleotide polymorphisms of the Plasmodium vivax dihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka.Analysis of Plasmodium vivax Apical Membrane Antigen-1 (PvAMA-1) Haplotypes among Iranian Isolates.
P2860
Q24617466-9F238C18-73D3-4BA4-B700-2541DC6986A0Q24622539-C2BF0363-CBC9-4604-AC3F-993933C266CFQ28478579-E02546EE-06CE-475A-9310-FBB4DD5FA051Q29619167-9F8A9723-EDC5-4715-849B-8E0CCC4A41C2Q31143848-298DD507-80A5-4F8D-962B-0316EAC046A3Q33828657-B74A39E4-8AB5-4A97-BB74-939ADE19F873Q33886228-6DB7D940-A0AA-478E-9429-B75031283CC6Q34259032-299BBE26-D181-4BAC-8AE4-3AACE2213B18Q34332235-37E6C321-1795-4F63-A4E2-7A225FE575BDQ34627183-ABB43B60-99AB-44AE-A224-BD338094B20AQ34772862-0093EB11-FB96-4B15-9142-7C4806E47CE1Q35062262-06C802B5-A24E-46AF-A536-BC1E0BF13421Q35131344-28DB4BE7-148C-4436-93C5-3713B6D595D2Q35867774-6906EB1C-807D-4713-B55C-15BBB909B9E5Q36064945-2AF6B66C-DED8-4C5E-864F-AF5FF5C47EFDQ36066272-1ACAFFFB-B454-4087-AD98-BAFE0424F7FCQ36094953-565CCEF8-EAA1-498B-B107-26DFD60B7296Q36185602-249CA5D0-6B15-45C6-A6CB-A7A8D24BA8F5Q36803894-F0308A62-809B-4272-9801-10FC36621FA8Q36895758-F1147A7C-F4A9-431F-83FA-3384534DB6A1Q36898219-24B80C75-6B5F-4486-9FD6-C3B7DB77B971Q37018629-44382EA8-EBC3-4134-AB6E-AE3C48153B2BQ37089624-652D12BA-E5B4-45FF-9F94-44E3535F781BQ37544412-72A4619E-C2A4-430A-AC81-AE6706526DABQ38731951-EFCB3AD5-A705-4F33-894C-8EC84101D7A7Q38842878-E5C83A80-B9A8-40C6-9B06-89CC15F1B88EQ41149881-42033D0F-12B6-406C-8769-F77912122607Q41913728-6C622172-C8FA-49FA-8DE8-39684A86E8CCQ41943390-67CDC44B-6CF8-41AD-ADD4-230CD62DF21AQ55475163-4C62B5FE-1DA3-4F51-A556-3BDE97ECC2A1
P2860
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
@ast
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
@en
type
label
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
@ast
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
@en
prefLabel
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
@ast
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
@en
P50
P921
P1433
P1476
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria.
@en
P2093
Malika Imwong
P304
P356
10.1016/J.ACTATROPICA.2003.10.012
P577
2004-02-01T00:00:00Z